Epirubicin Hydrochloride



Indications and Reactions:

Role Indications Reactions
Primary
Breast Cancer 39.2%
Pain 7.0%
Rhabdomyosarcoma 6.1%
Gastric Cancer 5.0%
Nausea 4.7%
Non-small Cell Lung Cancer 4.4%
Hepatic Neoplasm Malignant 4.0%
Breast Cancer Metastatic 3.8%
Hypertension 3.3%
Product Used For Unknown Indication 3.3%
Constipation 3.2%
Prophylaxis 2.9%
Chemotherapy 2.4%
Breast Cancer Female 2.2%
Sarcoma 1.6%
Bladder Cancer 1.6%
Insomnia 1.6%
Vomiting 1.4%
Analgesic Therapy 1.2%
Cancer Pain 1.2%
Neutropenia 13.2%
Interstitial Lung Disease 10.0%
Pneumonia 7.3%
Vomiting 5.9%
Sepsis 5.5%
White Blood Cell Count Decreased 5.5%
Leukopenia 5.0%
Cardiac Failure 4.6%
Febrile Neutropenia 4.6%
Progressive Multifocal Leukoencephalopathy 4.6%
Pyrexia 4.6%
General Physical Health Deterioration 4.1%
Anaemia 3.7%
Dyspnoea 3.7%
Respiratory Failure 3.7%
Pulmonary Embolism 3.2%
Death 2.7%
Nausea 2.7%
Neutropenic Colitis 2.7%
Pain 2.7%
Secondary
Breast Cancer 42.9%
Product Used For Unknown Indication 14.6%
Gastric Cancer 10.6%
Hodgkin's Disease 3.8%
Drug Use For Unknown Indication 3.8%
Breast Cancer Metastatic 3.3%
Therapeutic Embolisation 3.1%
Prophylaxis 2.7%
Her-2 Positive Breast Cancer 2.4%
Malignant Breast Neoplasm 1.6%
Prophylaxis Of Nausea And Vomiting 1.4%
Hepatic Neoplasm Malignant 1.3%
Chemotherapy 1.2%
Diffuse Large B-cell Lymphoma 1.2%
Pain 1.1%
Rhabdomyosarcoma 1.1%
Breast Cancer Female 1.0%
Non-hodgkin's Lymphoma 1.0%
Premedication 0.9%
Neoplasm Malignant 0.9%
Neutropenia 8.2%
Drug Exposure During Pregnancy 7.8%
Sepsis 7.0%
Death 6.1%
Febrile Neutropenia 6.1%
Pulmonary Embolism 5.3%
Pyrexia 5.3%
Vomiting 5.3%
Interstitial Lung Disease 4.9%
Septic Shock 4.9%
Diverticulitis Intestinal Haemorrhagic 4.5%
Acute Myeloid Leukaemia 4.1%
Alopecia 4.1%
Malignant Neoplasm Progression 4.1%
Pancreatitis 4.1%
Pneumonia 4.1%
Pancytopenia 3.7%
Thrombocytopenia 3.7%
Injection Site Phlebitis 3.3%
Ischaemic Stroke 3.3%
Concomitant
Breast Cancer 33.7%
Prophylaxis Of Nausea And Vomiting 13.1%
Metastases To Bone 7.7%
Breast Cancer Metastatic 7.3%
Product Used For Unknown Indication 6.2%
Therapeutic Embolisation 5.0%
Chemotherapy 3.7%
Premedication 3.5%
Hepatic Neoplasm Malignant 2.5%
Neoplasm Malignant 2.1%
Diffuse Large B-cell Lymphoma 2.0%
Hypertension 2.0%
Pain 2.0%
Breast Cancer Female 1.9%
Hepatocellular Carcinoma 1.5%
Breast Cancer Recurrent 1.3%
Prophylaxis 1.3%
Mineral Supplementation 1.1%
Nausea 1.1%
Acute Lymphocytic Leukaemia 0.9%
Hepatocellular Injury 9.5%
Cytolytic Hepatitis 7.1%
Injection Site Phlebitis 7.1%
No Adverse Event 7.1%
Flank Pain 6.0%
Osteonecrosis 6.0%
Injection Site Vasculitis 4.8%
Metastases To Liver 4.8%
Nausea 4.8%
Urinary Retention 4.8%
Vomiting 4.8%
White Blood Cell Count Decreased 4.8%
Acute Myeloid Leukaemia 3.6%
Cerebral Infarction 3.6%
Diabetes Mellitus 3.6%
Febrile Neutropenia 3.6%
Hepatitis Fulminant 3.6%
Hypertension 3.6%
Infusion Related Reaction 3.6%
Injection Site Erythema 3.6%
Interacting
Drug Use For Unknown Indication 57.1%
Breast Cancer 42.9%
Vomiting 75.0%
Pyrexia 25.0%